Carl Zeiss Meditec AG (XSWX:AFX) Cash per Share: CHF0.00 (As of Dec. 2025)

What is Carl Zeiss Meditec AG Cash per Share?

Carl Zeiss Meditec AG XSWX:AFX 70 Cash per Share is CHF0.00 as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 70/100 and a GF Value™ of CHF314.64 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Carl Zeiss Meditec AG's Cash per Share for the quarter that ended in Dec. 2025 was CHF0.00.

Carl Zeiss Meditec AG (XSWX:AFX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Carl Zeiss Meditec AG Cash per Share Related Terms

Carl Zeiss Meditec AG Cash per Share Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Cash per Share Chart

Carl Zeiss Meditec AG Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

Cash per Share

Get a 7-Day Free Trial

0.09

0.08

0.11

0.22

0.29

Carl Zeiss Meditec AG Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
Cash per Share	Get a 7-Day Free Trial															0.00	0.56	0.00	0.29	0.00

70GF Score

Carl Zeiss Meditec AG XSWX:AFX

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Carl Zeiss Meditec AG Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Carl Zeiss Meditec AG's Cash per Share for the fiscal year that ended in Sep. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	25.478	/	88
	=	0.29

Carl Zeiss Meditec AG's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0	/	88
	=	0.00

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of CHF0.00 mean?

Carl Zeiss Meditec AG (XSWX:AFX) has a Cash per Share of CHF0.00 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Carl Zeiss Meditec AG and its competitors.

Is Carl Zeiss Meditec AG's Cash per Share too high?

Carl Zeiss Meditec AG's current Cash per Share is CHF0.00. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Carl Zeiss Meditec AG's Cash per Share compare to ISRG and BDX?

Carl Zeiss Meditec AG's Cash per Share of CHF0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Medical Devices & Instruments company?

A good Cash per Share depends on the Medical Devices & Instruments industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Cash per Share is CHF0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Carl Zeiss Meditec AG stock overvalued right now?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF314.64, compared to a current price of CHF26.30 — trading 91.6% below its estimated fair value. The current Cash per Share is CHF0.00. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Cash per Share is CHF0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF26.30 is trading 91.6% below its estimated GF Value™ of CHF314.64. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

Cash per Share: CHF0.00
GF Value™: CHF314.64 vs. price of CHF26.30 (91.6% below fair value)
GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies XTER:1SXP XTER:FIE XTER:GXI FRA:PHH2 ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543 XPAR:DIM COO SOLV OCSE:COLO B NZSE:FPH ALGN

Other Exchanges CZMWY:USA CZMWF:USA 1AFX:Italy AFXd:UK 0DHC:UK AFX:Germany AFX:Austria

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745

Website https://www.zeiss.com

Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.

70GF Score

Get the complete analysis for XSWX:AFX

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.30

Price

CHF314.64

GF Value

View XSWX:AFX Analysis

See Cash per Share data for all stocks →